PP_1170x120_10-25-21

Belviq XR

Eisai acquires global rights to Belviq from Arena

Eisai acquires global rights to Belviq from Arena

WOODCLIFF LAKE, N.J. — Eisai Inc. has entered an agreement with Arena Pharmaceuticals Inc. to acquire all global development and marketing rights for Belviq and Belviq XR (lorcaserin hydrochloride), a chronic weight management treatment. Eisai said the agreement amends its November 2013 marketing and supply pact with  Arena Pharmaceuticals GmbH. Under the deal announced this

Eisai, Arena release Belviq XR weight-loss tablets

Eisai, Arena release Belviq XR weight-loss tablets

WOODCLIFF LAKE, N.J. and SAN DIEGO — Eisai Inc. and Arena Pharmaceuticals Inc. have launched Belviq XR (lorcaserin HCl) CIV extended-release 20-mg tablets, a weight-loss medication. The companies said Belviq XR, approved by the Food and Drug Administration in July, offers a new once-daily dosing option that may help some patients achieve and maintain weight